Q2 Earnings Forecast for TG Therapeutics by B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) has recently caught the attention of analysts, particularly those at B. Riley. On March 4th, B. Riley released their earnings per share (EPS) estimates for TG Therapeutics for the second quarter of 2025. Analyst M. Mamtani expressed optimism, predicting the biopharmaceutical company will report earnings of $0.27 per share for that quarter.

The current consensus estimate for TG Therapeutics' earnings for the entire year is significantly lower at $0.08 per share. Looking ahead, B. Riley's forecasts extend to subsequent quarters with expectations of $0.26 EPS for Q3 2025, $0.28 EPS for Q4 2025, and an annual target of $1.03 EPS for FY2025. Long-term projections foresee EPS of $2.78 for FY2027, $3.85 for FY2028, and $4.74 for FY2029.

In a recent earnings announcement on March 3rd, TG Therapeutics reported earnings of $0.15 EPS, surpassing analysts' expectations of $0.08 by $0.07. The company generated $108.19 million in revenue, also exceeding the forecast of $100.67 million set by analysts. Despite the positive earnings results, TG Therapeutics has struggled with a negative net margin of 5.42% and a negative return on equity of 8.32%.

Recent Analyst Ratings

Analysts remain particularly interested in the company's stock performance. Other research analysts have weighed in with varying perspectives. StockNews.com recently upgraded TG Therapeutics from a "sell" rating to a "hold" rating. Meanwhile, HC Wainwright reiterated a "buy" rating and set a target price of $55.00 for the shares. Additionally, JPMorgan Chase & Co. raised their price target for TG Therapeutics from $30.00 to $43.00 and assigned an "overweight" rating.

In total, two analysts recommend holding the stock while five have issued buy ratings. Current data from MarketBeat shows that TG Therapeutics holds a consensus rating of "Moderate Buy" with an average price target of $40.67.

Stock Performance Overview

On the trading floor, shares of TG Therapeutics opened at $35.19 on the previous Friday. The stock has shown considerable volatility over the past year, with a low of $12.93 and a high of $37.58. Currently, the company carries a market capitalization of approximately $5.48 billion and has a price-to-earnings ratio of -351.86 with a beta of 2.30.

Insider Trading Activity

In insider trading news, CFO Sean A. Power sold a total of 11,337 shares on January 3rd at an average price of $30.29, amounting to $343,397.73 for the transaction. Despite this sale, Power retains ownership of 670,632 shares valued at $20,313,443.28, reflecting a 1.66% decrease in their stake. Overall, 10.50% of TG Therapeutics' stock is owned by insiders.

Institutional Investment Movements

Institutional trading for TG Therapeutics has also seen activity. The Arizona State Retirement System increased its stake by 0.9% in the fourth quarter, holding 42,639 shares valued at about $1.28 million after acquiring more shares. Similarly, Blue Trust Inc. raised its holdings by 24.5% and now owns 1,887 shares worth $57,000. These movements suggest that institutional interest in TG Therapeutics is strong, with 58.58% of shares held by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatment options for diseases mediated by B-cells, both in the United States and internationally. The company markets BRIUMVI, an anti-CD20 monoclonal antibody specifically for treating adult patients with various forms of multiple sclerosis.

Earnings, Forecast, Analysts